JP2023506227A5 - - Google Patents
Info
- Publication number
- JP2023506227A5 JP2023506227A5 JP2022535965A JP2022535965A JP2023506227A5 JP 2023506227 A5 JP2023506227 A5 JP 2023506227A5 JP 2022535965 A JP2022535965 A JP 2022535965A JP 2022535965 A JP2022535965 A JP 2022535965A JP 2023506227 A5 JP2023506227 A5 JP 2023506227A5
- Authority
- JP
- Japan
- Prior art keywords
- hours
- minutes
- days
- ptpn2
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2026031034A JP2026094293A (ja) | 2019-12-12 | 2026-02-27 | 免疫活性を強化するための組成物および方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962947483P | 2019-12-12 | 2019-12-12 | |
| US62/947,483 | 2019-12-12 | ||
| PCT/US2020/064709 WO2021119554A1 (en) | 2019-12-12 | 2020-12-11 | Compositions and methods for potentiating immune activity |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026031034A Division JP2026094293A (ja) | 2019-12-12 | 2026-02-27 | 免疫活性を強化するための組成物および方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023506227A JP2023506227A (ja) | 2023-02-15 |
| JP2023506227A5 true JP2023506227A5 (cg-RX-API-DMAC7.html) | 2023-12-18 |
Family
ID=76329104
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022535965A Pending JP2023506227A (ja) | 2019-12-12 | 2020-12-11 | 免疫活性を強化するための組成物および方法 |
| JP2026031034A Pending JP2026094293A (ja) | 2019-12-12 | 2026-02-27 | 免疫活性を強化するための組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026031034A Pending JP2026094293A (ja) | 2019-12-12 | 2026-02-27 | 免疫活性を強化するための組成物および方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US12551555B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4073242A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2023506227A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115103907A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020401376A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3163012A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021119554A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020401376A1 (en) | 2019-12-12 | 2022-06-30 | Kumquat Biosciences Inc. | Compositions and methods for potentiating immune activity |
| CN114668743B (zh) * | 2021-08-04 | 2025-08-08 | 贵州医科大学附属医院 | 抑制黑色素瘤生长的纳米载药系统的制备方法及应用 |
| CN116251099B (zh) * | 2023-04-30 | 2026-07-24 | 兰州大学第二医院 | 含苯氧基乙酰肼化合物的胰腺癌jak2和stat3双靶向抑制剂及应用 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE534637T1 (de) | 2002-04-03 | 2011-12-15 | Novartis Ag | 5-substituierte 1,1-dioxo- 1,2,5 thiazolidin-3- onderivate als ptpase 1b hemmer |
| GB0225986D0 (en) | 2002-11-07 | 2002-12-11 | Astrazeneca Ab | Chemical compounds |
| UA94724C2 (en) | 2005-12-08 | 2011-06-10 | Новартис Аг | Thiadiazolidinone derivatives as antidiabetic agents |
| UA94921C2 (en) | 2005-12-08 | 2011-06-25 | Новартис Аг | 1-orthofluorophenyl substituted 1, 2, 5-thiazolidinedione derivatives as ptp-as inhibitors |
| RU2008127253A (ru) | 2005-12-08 | 2010-01-20 | Новартис АГ (CH) | 1,1,3-триоксо-1,2,5-тиадиазолидины и их применение в качестве ингибиторов птфаз |
| JP2009532379A (ja) | 2006-03-31 | 2009-09-10 | ノバルティス アクチエンゲゼルシャフト | PTPaseのチアジアゾリジノン阻害剤 |
| AR066820A1 (es) | 2007-06-04 | 2009-09-16 | Novartis Ag | Compuestos de tiadiazolidin-3 ona |
| WO2009049098A2 (en) | 2007-10-09 | 2009-04-16 | Indiana University Research & Technology Corporation | Materials and methods for regulating the activity of phosphatases |
| US9217012B2 (en) * | 2009-04-08 | 2015-12-22 | Indiana University Research And Technology Corporation | Inhibitors of protein tyrosine phosphatases |
| CN103561573A (zh) | 2011-04-26 | 2014-02-05 | 印第安纳大学研究与技术公司 | 酪氨酸磷酸酶及其在调节参与结核分枝杆菌之病理学的酶的活性中的用途 |
| CA2977839C (en) * | 2014-02-28 | 2022-07-26 | The Royal Institution For The Advancement Of Learning / Mcgill University | Tc-ptp inhibitors as apc activators for immunotherapy |
| JP2017524348A (ja) * | 2014-06-10 | 2017-08-31 | モナッシュ ユニバーシティ | 養子細胞移入のためのptpn2阻害を用いた白血球の産生方法 |
| IL308735A (en) * | 2015-07-01 | 2024-01-01 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
| KR101826690B1 (ko) * | 2015-11-06 | 2018-03-22 | 경북대학교 산학협력단 | 단백질 타이로신 탈인산화효소 억제제를 포함하는 신경염증성 질환의 예방 또는 치료용 조성물 |
| US11311543B2 (en) | 2016-05-27 | 2022-04-26 | Yale University | Compositions and methods for inhibiting PTPN22 |
| WO2018227248A1 (en) * | 2017-06-13 | 2018-12-20 | Monash University | Methods and compositions for the treatment of obesity |
| WO2019036815A1 (en) | 2017-08-24 | 2019-02-28 | The Royal Institution For The Advancement Of Learning/Mcgill University | ENHANCEMENT OF CD8 + T LYMPHOCYTES FOR ADOPTIVE CELL THERAPY BY INHIBITING PTPN1 (PTP1B) AND PTPN2 (TC-PTP)) |
| WO2019178422A1 (en) * | 2018-03-15 | 2019-09-19 | KSQ Therapeutics, Inc. | Gene-regulating compositions and methods for improved immunotherapy |
| TWI888352B (zh) | 2018-06-21 | 2025-07-01 | 美商嘉來克生命科學有限責任公司 | 蛋白質酪胺酸磷酸酯酶抑制劑及其使用方法 |
| US20220081691A1 (en) * | 2018-08-07 | 2022-03-17 | Dana-Farber Cancer Institute, Inc | Modulating ptpn2 to increase immune responses and perturbing gene expression in hematopoietic stem cell lineages |
| KR102983496B1 (ko) | 2019-03-14 | 2026-06-29 | 칼리코 라이프 사이언시스 엘엘씨 | 단백질 티로신 포스파타제 억제제 및 이의 사용 방법 |
| AU2020395612A1 (en) | 2019-12-04 | 2022-06-09 | Monash University | Methods of activating cytotoxic leukocytes using PTP1B and PTPN2 inhibitors |
| AU2020401376A1 (en) | 2019-12-12 | 2022-06-30 | Kumquat Biosciences Inc. | Compositions and methods for potentiating immune activity |
| MX2022007441A (es) | 2019-12-18 | 2022-09-02 | Calico Life Sciences Llc | Inhibidores de proteína tirosina fosfatasa y sus métodos de uso. |
| CN116194453A (zh) | 2019-12-20 | 2023-05-30 | 卡里科生命科学有限责任公司 | 蛋白质酪氨酸磷酸酶降解剂及其使用方法 |
| CN113827727B (zh) | 2020-06-24 | 2025-04-29 | 上海交通大学医学院附属瑞金医院 | Ptpn2抑制剂在kras突变肿瘤中的应用 |
| EP4211122A1 (en) | 2020-09-11 | 2023-07-19 | Calico Life Sciences LLC | Protein tyrosine phosphatase inhibitors and methods of use thereof |
-
2020
- 2020-12-11 AU AU2020401376A patent/AU2020401376A1/en active Pending
- 2020-12-11 WO PCT/US2020/064709 patent/WO2021119554A1/en not_active Ceased
- 2020-12-11 CA CA3163012A patent/CA3163012A1/en active Pending
- 2020-12-11 CN CN202080096581.7A patent/CN115103907A/zh active Pending
- 2020-12-11 EP EP20898012.8A patent/EP4073242A4/en active Pending
- 2020-12-11 JP JP2022535965A patent/JP2023506227A/ja active Pending
-
2022
- 2022-06-10 US US17/838,064 patent/US12551555B2/en active Active
-
2026
- 2026-02-27 JP JP2026031034A patent/JP2026094293A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7857980B2 (ja) | Cd19指向性キメラ抗原受容体および免疫療法におけるその使用 | |
| CN113286879B (zh) | 用于细胞疗法之多样化抗原结合域、新颖平台及其他增强子 | |
| JP2024520676A5 (cg-RX-API-DMAC7.html) | ||
| JP2021525509A5 (cg-RX-API-DMAC7.html) | ||
| ES2988584T3 (es) | Subconjunto de células NKT para persistencia y actividad terapéutica in vivo y propagación del mismo | |
| IL273201B1 (en) | Novel platforms for co-stimulation, novel car designs and other enhancements for adoptive cellular therapy | |
| JP2019534246A5 (cg-RX-API-DMAC7.html) | ||
| CN110352068A (zh) | 合成的免疫受体及其使用方法 | |
| EP3612222A1 (en) | Compositions and methods for treating cancer | |
| US20160015749A1 (en) | Engager cells for immunotherapy | |
| JP2019532997A5 (cg-RX-API-DMAC7.html) | ||
| JP2024509095A5 (cg-RX-API-DMAC7.html) | ||
| JP2020511462A5 (cg-RX-API-DMAC7.html) | ||
| WO2022199125A1 (zh) | 一种自分泌IL-15与anti-PD1融合蛋白的免疫细胞 | |
| JP7186615B2 (ja) | 遺伝子操作された薬物耐性t細胞およびその使用方法 | |
| JP2024519335A (ja) | がん免疫療法のための投薬レジメン | |
| US12178786B2 (en) | Combination of cellular immunotherapy | |
| JP2024531446A5 (cg-RX-API-DMAC7.html) | ||
| JP7541390B2 (ja) | 免疫チェックポイント分子と結合可能な分子が融合したタンパク質およびその用途 | |
| CN112638428A (zh) | 嵌合抗原受体肿瘤浸润淋巴细胞 | |
| JP2018526453A5 (cg-RX-API-DMAC7.html) | ||
| JP2025513607A (ja) | Cd7遺伝子がノックアウトされた操作された免疫細胞及びその用途 | |
| GB2623191A (en) | Engineered chimeric fusion protein compositions and methods of use thereof | |
| TW201938196A (zh) | 融合蛋白擴展 | |
| WO2020142780A1 (en) | Car t cell methods and constructs |